Rajani Ravi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11865871/publications.pdf Version: 2024-02-01



ΡΑΙΑΝΙ ΡΑΥΙ

#	Article	IF	CITATIONS
1	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nature Communications, 2018, 9, 741.	5.8	238
2	SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clinical Cancer Research, 2017, 23, 5162-5175.	3.2	64
3	In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia. Cell Death Discovery, 2017, 3, 17022.	2.0	27
4	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 376-382.	0.8	50
5	Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nature Communications, 2015, 6, 8258.	5.8	129
6	Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells. International Journal of Molecular Medicine, 2014, 34, 941-946.	1.8	164
7	The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors. Cancer Research, 2014, 74, 3995-4005.	0.4	123
8	Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy. Molecular Cancer Therapeutics, 2012, 11, 2429-2439.	1.9	66
9	OGDHL Is a Modifier of AKT-Dependent Signaling and NF-κB Function. PLoS ONE, 2012, 7, e48770.	1.1	56
10	Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance. PLoS ONE, 2011, 6, e20806.	1.1	61
11	Regulation of p53 Family Member Isoform ΔNp63α by the Nuclear Factor-κB Targeting Kinase IκB Kinase β. Cancer Research, 2010, 70, 1419-1429.	0.4	41
12	Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2255-2264.	1.9	184
13	â€~The Metabolism of Tumours': 70 Years Later. Novartis Foundation Symposium, 2008, , 251-264.	1.2	152
14	Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. Journal of Nanobiotechnology, 2007, 5, 3.	4.2	861
15	Resistance of Cancers to Immunologic Cytotoxicity and Adoptive Immunotherapy via X-Linked Inhibitor of Apoptosis Protein Expression and Coexisting Defects in Mitochondrial Death Signaling. Cancer Research, 2006, 66, 1730-1739.	0.4	41
16	Elimination of Hepatic Metastases of Colon Cancer Cells via p53-Independent Cross-Talk between Irinotecan and Apo2 Ligand/TRAIL. Cancer Research, 2004, 64, 9105-9114.	0.4	66
17	NF-κB in cancer—a friend turned foe. Drug Resistance Updates, 2004, 7, 53-67.	6.5	131
18	Potential methods to circumvent blocks in apoptosis in lymphomas. Current Opinion in Oncology, 2002, 14, 490-503.	1.1	11

Rajani Ravi

#	Article	IF	CITATIONS
19	Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Research, 2002, 62, 1583-7.	0.4	102
20	Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Research, 2002, 62, 4180-5.	0.4	86
21	Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF- $\hat{1}^{e}$ B. Nature Cell Biology, 2001, 3, 409-416.	4.6	316
22	Conversion of Bcl-2 to a Bax-like Death Effector by Caspases. Science, 1997, 278, 1966-1968.	6.0	1,028